What FDA compliance steps must a Turkish manufacturer take to export dietary supplements to the United States?

Hello. To export dietary supplements to the U.S., you need to complete FDA Facility Registration. Additionally, your product labeling must strictly comply with U.S. regulations. Since non-compliance can lead to detention of goods, professional legal assistance is recommended to navigate these steps correctly.

This is not mainly an FDA approval question. It is a pre-export compliance question. FDA generally does not pre-approve dietary supplements before sale. The real issue is whether your Turkish facility, formula, label, and import setup are already compliant before the first shipment leaves Turkey.

At facility level, a Turkish manufacturer exporting supplements to the U.S. will usually need FDA food facility registration, and a foreign facility must appoint a U.S. agent. Registration itself does not carry an FDA fee, but it must be kept current and renewed biennially. If the facility manufactures, packages, labels, or holds dietary supplements for the U.S. market, it must also comply with dietary supplement CGMP requirements under 21 CFR Part 111.

At product level, the label cannot be a simple English translation of the Turkish label. It must be rebuilt for the U.S. market: lawful Supplement Facts, ingredient naming, serving size format, claim language, the required disclaimer where applicable, and a domestic U.S. address or phone number for serious adverse event reporting. If the product uses structure/function claims, FDA notification may be required within 30 days after first marketing. If it contains a new dietary ingredient, a 75-day premarket notification may be necessary before launch.

At import level, every shipment must be coordinated correctly. Dietary supplements are treated as food for import purposes, so prior notice is generally required before arrival in the United States. On the U.S. side, importer-side FSVP obligations must also be checked, although dietary supplements can fall under modified requirements depending on the product and import structure.

In practice, most problems arise not from the formula itself, but from claims, labeling, weak specifications, poor batch documentation, or an incomplete U.S. import setup. That is why the right sequence is not manufacture first and fix later. The right sequence is compliance review first, shipment second.

So yes, you will usually need a U.S.-based agent for facility registration, but that alone is not enough. The real work is building a compliant entry file: registration, U.S. agent, label review, CGMP records, claim analysis, ingredient assessment, prior notice workflow, and importer coordination. If those pieces are handled correctly before export, U.S. entry is usually manageable. If they are ignored, the product can be delayed, detained, or rejected at the border.

The real value here is not filing one form. It is preventing detention, relabeling costs, and a failed first shipment before they happen.